Wiesbaden, Germany – Last night Bavarian Nordic dropped the unfortunate news that the phase 3 PROSPECT trial exploring the PROSTVAC vaccine in combination with GM-CSF in asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer (CRPC) was futile.
Once you miss the overall survival (OS) endpoint, that’s it folks – there’s no other choice but to say the therapy failed, harsh though that may sound.
There are, however, a number of important points to consider from here that are worthy of further discussion.
Here, we post an analytical review and look at a number of factors that could have impacted the outcome. It’s rarely one simple thing because the immune system is highly complex and multi-faceted.
Hopefully there will be important learnings from this study that will advance the IO and prostate cancer fields.